The JPT2 antibody targets Junction Plakoglobin (JUP), also known as γ-catenin, a key component of cell-cell adhesion structures like desmosomes and adherens junctions. JUP plays dual roles: it stabilizes intercellular connections by linking cadherins to the actin cytoskeleton and participates in Wnt/β-catenin signaling, influencing cell proliferation and differentiation. Dysregulation of JUP is implicated in pathologies such as arrhythmogenic cardiomyopathy (AC), where mutations disrupt desmosomal integrity, leading to fibrofatty myocardial replacement. In cancer, reduced JUP expression correlates with epithelial-mesenchymal transition (EMT), metastasis, and poor prognosis, particularly in carcinomas. The JPT2 antibody is widely utilized in research to visualize JUP localization via immunofluorescence or immunohistochemistry, assess protein levels in Western blotting, and investigate molecular mechanisms in disease models. Its applications extend to studying desmosomal disorders, cardiac pathologies, and cancer biology, making it a critical tool for exploring cell adhesion dynamics and signaling pathways. Commercial JPT2 antibodies are typically raised in rabbits or mice, validated for reactivity in human, mouse, and rat tissues.